Table 1.

Clinicopathologic and genomic comparison of IPMs versus SPLCs for paired adenocarcinomas

	IPM	SPLCs	P
Patient characteristics	N total = 17 patients	N total = 37 patients
No. of analyzed tumors per patient
Two tumors	14 (82%)	32 (86%)	0.70
Three tumors	3 (18%)	5 (14%)
Smoking history
Current/former	10 (59%)	32 (86%)	0.035
Never	7 (41%)	5 (14%)
Pack years
Mean (range)	14 (0–50)	34 (0–118)	0.007
Median	7.5	30
Background multiple (>1) AAH	0	11 (30%)	0.011
Staging parameters
Tumor size mean (range); cm	2.5 (0.6–9.7)	2.0 (0.5–9.0)	0.17
pN1 or pN2 at time of surgery	8 (47%)	14 (38%)	0.56
pM1b (distant metastasis) at time of surgery	0	0	1.00
Tumor pair comparisons	N total = 23 tumor pairs	N total = 47 tumor pairs
Time course
Synchronous	9 (39%)	40 (85%)	0.0002
Metachronous	14 (61%)	7 (15%)
Latency for metachronous tumors
Mean (range); years	3.6 (0.4–7.6)	1.6 (0.6–2.7)	0.038
Intrapulmonary relationship
Ipsilateral same lobe	6 (26%)	20 (43%)	0.37
Ipsilateral other lobe	9 (39%)	16 (34%)
Contralateral lobe	8 (35%)	11 (23%)
Histologic pattern in any amount in at least one of the paired tumors
- Lepidic	17 (74%)	41 (87%)	0.19
- Acinar	22 (96%)	47 (100%)	0.33
- Papillary	13 (57%)	23 (49%)	0.62
- Micropapillary	21 (91%)	34 (72%)	0.12
- Solid	8 (35%)	20 (43%)	0.61
- Either micropapillary or solid	23 (100%)	39 (83%)	0.046
Lepidic in both tumors	14 (61%)	25 (53%)	0.61
Micropapillary in both tumors	15 (65%)	15 (32%)	0.01
Individual tumor comparisons	N total = 17 unique tumors	N total = 79 unique tumors
Driver alterations
EGFR mutations	4 (23%)	13 (16%)	0.49
ALK fusion	1 (6%)	1 (1%)	0.32
ROS1 fusion	1 (6%)	1 (1%)	0.32
MET exon 14 mutations	4 (23%)	2 (3%)	0.0085
BRAF V600E mutation	1 (6%)	0	0.18
KRAS mutations	5 (30%)	43 (54%)	0.11
Other driver alterations	0	9 (11%)	0.35
Unknown driver	1 (6%)	10 (13%)	0.68
Non-KRAS drivers (EGFR, ALK, ROS1, MET, and BRAF)	11 (65%)	17 (22%)	0.0009
TMB
Mean (range); mt/Mb	4.5 (0.9–15.8)	7.0 (0–41.2)	0.025

Abbreviation: TMB, tumor mutation burden.